The California biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag in combination with tirzepatide ...
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut ...
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
A Johns Hopkins surgeon, Marty Makary also serves as a board member or adviser to several companies, including one that ...
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...
The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory ...
The NYPD confirmed the shooting, which caused UnitedHealth to end an investor conference early on Wednesday. Thompson, 50, ...
The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to ...
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to ...